Ion channel phosphorylopathy: a link between genomic variation and human disease
Related Experiment Video
Updated: May 19, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
1Department of Molecular Pharmacology and Therapeutics, Loyola University Medical Center, 2160 South First Ave., Bldg. 102, Rm. 3621, Maywood, IL 60153, USA. sagentile@lumc.edu
Abstract:
Voltage-gated ion channels (VGIC) regulate many important physiological events, including muscle contraction, brain function, and secretion. Mutations that inhibit or up-regulate VGIC activities can dramatically interfere with the normal function of several organs, leading to unpredictable failure and therefore poor quality of life or even death. Many genomic variations that change amino acids in cytoplasmic domains of ion channels have been found to be associated with several diseases, including cardiac arrhythmias and neurodegeneration. However, a mechanism linking these mutations to ion channel malfunction has not been clearly established and in some cases is totally unknown. This concept article gives an overview on a possible mechanism by which disease-associated mutations in cytoplasmic domains of ion channels can affect channel activity by creating or disrupting phosphorylation sites for specific kinases. We call these events "ion channel phosphorylopathies". Understanding ion channel phosphorylopathies offers the opportunity to find a mechanism linking genomic variations to human disease and is crucial to the process of designing an effective pharmacological strategy.
Insights
Disease-associated mutations in voltage-gated ion channels (VGIC) may cause malfunction by altering phosphorylation sites. Understanding these "ion channel phosphorylopathies" is key to developing new treatments for related human diseases.
Area of Science:
- Biophysics
- Molecular Biology
- Human Physiology
Background:
- Voltage-gated ion channels (VGIC) are crucial for physiological processes like muscle contraction and neural signaling.
- Mutations in VGIC can lead to severe organ dysfunction, impacting patient quality of life and survival.
- Genomic variations in cytoplasmic domains of ion channels are linked to diseases such as cardiac arrhythmias and neurodegeneration.
Purpose of the Study:
- To propose a mechanism linking disease-associated mutations in VGIC cytoplasmic domains to channel malfunction.
- To introduce the concept of "ion channel phosphorylopathies" as a potential molecular basis for these diseases.
Main Methods:
- This is a concept article, presenting a theoretical framework.
- It reviews existing knowledge on VGIC structure, function, and disease-associated mutations.
- It synthesizes information to propose a novel mechanism involving kinase phosphorylation sites.
Main Results:
- Disease-associated mutations in VGIC cytoplasmic domains may create or disrupt critical phosphorylation sites.
- These alterations in phosphorylation can directly impact ion channel activity and function.
- This mechanism provides a potential link between genomic variations and observed channelopathies.
Conclusions:
- "Ion channel phosphorylopathies" offer a unifying mechanism for understanding how genetic variations cause ion channel dysfunction.
- Understanding this mechanism is crucial for developing targeted pharmacological strategies for diseases linked to VGIC mutations.
- Further research into ion channel phosphorylation is warranted to validate this concept and its therapeutic implications.
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life

